// App-Quantinova.ai

: Limited Long-Term Benefit of Upfront Autologous Stem Cell Transplant on Survival in Severe Renal Impairment in Multiple Myeloma in Novel Drug Era, a Retrospective Multi-Center Study in China

Researchers

Presenter

  • Huixing Zhou

Principal Investigators

  • Yuan Jian

  • Weiwei Xie

  • Yuan Ren

  • Zhiyao Zhang

  • Guangzhong Yang

  • Chuanying Geng

  • Jing Jia

  • Wenming Chen

  • Jian Li

  • Wenrong Huang

  • Xinan Cen

  • Wen Gao

Medical Centers

  • Department of Hematology, Fifth Medical Ccenter, General Hospital of the people's Liberation Army, Beijing, China

  • Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

  • Department of Hematology, Beijing Chao-Yang Hospital, Capital Medical University, Beijing, China

  • Peking University First Hospital, Beijing, China

Locations

  • China

Companies

  • N/A

Study Components

Therapeutic Area

  • Nephrology

  • Oncology (ONC)

Disease

  • Multiple Myeloma

  • Renal insufficiency

  • Renal disease

Biomarkers

  • Creatinine

  • Estrogen receptor alpha

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Multinational

  • Multicenteric

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved